Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
Dylan Alexander Carlin, Jamaica Plain, MA (US); Vincent M. Isabella, Medford, MA (US); Jonathan McMurry, Boston, MA (US); Theodore Carlton Moore, III, Cambridge, MA (US); Mylene Perreault, Lexington, MA (US); Nathan Schmidt, Milton, MA (US); and Mark Simon, Gainesville, FL (US)
Assigned to Synlogic Operating Company, Inc., Cambridge, MA (US); and Ginkgo Bioworks, Inc., Boston, MA (US)
Filed by Synlogic Operating Company, Inc., Cambridge, MA (US); and Ginkgo Bioworks, Inc., Boston, MA (US)
Filed on Aug. 11, 2022, as Appl. No. 17/819,086.
Claims priority of provisional application 63/231,773, filed on Aug. 11, 2021.
Claims priority of provisional application 63/281,178, filed on Nov. 19, 2021.
Claims priority of provisional application 63/282,319, filed on Nov. 23, 2021.
Claims priority of provisional application 63/326,323, filed on Apr. 1, 2022.
Claims priority of provisional application 63/355,819, filed on Jun. 27, 2022.
Prior Publication US 2023/0063093 A1, Mar. 2, 2023
a heterologous methionine decarboxylase (metDC) gene operably linked to a promoter, wherein the heterologous metDC gene encodes a polypeptide comprising SEQ ID NO: 1048.